Latest Ratios: P/E Ratio 12.7x · EV/EBITDA 28.3x · ROE 4.1%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $15M | $88M | $421M | $170M | — | — | — | — | — |
| Enterprise Value | $26M | $100M | $424M | $167M | — | — | — | — | — |
| P/E Ratio → | 12.73 | 75.33 | 114.47 | 59.09 | — | — | — | — | — |
| P/S Ratio | 0.72 | 4.28 | 17.91 | 8.57 | — | — | — | — | — |
| P/B Ratio | 0.51 | 2.99 | 14.74 | 7.08 | — | — | — | — | — |
| P/FCF | — | — | — | 56.75 | — | — | — | — | — |
| P/OCF | 5.15 | 30.46 | — | 54.66 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.83 | 18.06 | 8.42 | — | — | — | — | — |
| EV / EBITDA | 28.30 | 107.09 | 106.50 | 53.99 | — | — | — | — | — |
| EV / EBIT | 43.41 | 164.26 | 116.63 | 58.24 | — | — | — | — | — |
| EV / FCF | — | — | — | 55.80 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.2% | 29.2% | 40.4% | 34.2% | 32.3% | 30.6% | 34.0% | 36.9% | 36.6% |
| Operating Margin | 2.9% | 2.9% | 15.5% | 14.5% | 11.1% | 12.7% | 14.5% | 21.6% | 20.2% |
| Net Profit Margin | 5.8% | 5.8% | 15.6% | 14.5% | 14.1% | 12.7% | 13.6% | 17.9% | 17.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.1% | 4.1% | 14.0% | 14.7% | 18.5% | 21.2% | 20.5% | 37.0% | 40.9% |
| ROA | 2.4% | 2.4% | 9.3% | 10.7% | 12.6% | 12.3% | 10.7% | 18.7% | 19.7% |
| ROIC | 1.2% | 1.2% | 10.3% | 13.6% | 15.4% | 17.8% | 15.1% | 32.2% | 35.8% |
| ROCE | 2.1% | 2.1% | 13.8% | 14.6% | 14.6% | 21.2% | 21.9% | 44.7% | 47.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.64 | 0.64 | 0.41 | 0.17 | — | — | 0.25 | 0.27 | 0.08 |
| Debt / EBITDA | 20.27 | 20.27 | 2.91 | 1.33 | — | — | 0.99 | 0.60 | 0.16 |
| Net Debt / Equity | — | 0.39 | 0.12 | -0.12 | -0.31 | -0.26 | 0.09 | 0.09 | -0.02 |
| Net Debt / EBITDA | 12.27 | 12.27 | 0.87 | -0.91 | -1.93 | -1.24 | 0.37 | 0.20 | -0.03 |
| Debt / FCF | — | — | — | -0.94 | -3.11 | -0.63 | 0.42 | — | — |
| Interest Coverage | — | — | — | — | — | 304.45 | 21.93 | 192.76 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | 1.86 | 2.50 | 3.49 | 3.31 | 2.47 | 1.81 | 1.83 | 1.61 |
| Quick Ratio | 1.65 | 1.65 | 2.08 | 2.83 | 2.11 | 1.57 | 1.09 | 1.24 | 0.99 |
| Cash Ratio | 1.25 | 1.25 | 1.56 | 1.87 | 1.24 | 0.73 | 0.28 | 0.35 | 0.25 |
| Asset Turnover | — | 0.39 | 0.51 | 0.60 | 0.92 | 0.95 | 0.78 | 1.00 | 1.12 |
| Inventory Turnover | 2.97 | 2.97 | 1.97 | 2.23 | 1.89 | 2.05 | 1.47 | 2.24 | 2.19 |
| Days Sales Outstanding | — | 120.02 | 136.29 | 156.53 | 80.87 | 105.11 | 177.19 | 154.59 | 110.70 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.9% | 1.3% | 0.9% | 1.7% | — | — | — | — | — |
| FCF Yield | — | — | — | 1.8% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $8M | $8M | $7M | $7M | $13M | $20M | $20M | $20M |
Export market demand volatility
According to recent market data, ZJYL trades at an EV/EBITDA of 31.24, which appears significantly elevated relative to its historical performance and the company's current inability to generate consistent, high-quality earnings growth, suggesting that investors may be overestimating the firm's long-term competitive positioning in the medical supply sector.
The current P/S ratio of 0.86, when viewed alongside the lack of a forward P/E, implies that the market is struggling to price the company's volatile earnings trajectory. This valuation suggests a speculative premium that may not be supported by the underlying contraction in revenue and the compression of operating margins.
Based on reported financial statements, ZJYL's ROIC has trended downward from 12.8% in 2021Q2 to 2.2% in 2025Q4, indicating that the company is failing to compound returns on its invested capital as it shifts toward a more capital-intensive manufacturing model with lower operational efficiency.
The decline in ROIC suggests that recent investments in property, plant, and equipment are not yielding the expected incremental returns. This trend warrants further investigation into whether the company's capital allocation strategy is prioritizing growth over the preservation of shareholder value.
As reported in recent filings, ZJYL's cash conversion cycle has fluctuated significantly, reaching 82 days in 2025Q4, which highlights the company's ongoing struggle to optimize inventory turnover and manage distributor payment cycles effectively in a challenging export environment.
The increase in days inventory outstanding suggests that the company may be holding excess stock, potentially due to slowing demand in its primary Japanese markets. This inefficiency ties up critical liquidity and increases the risk of inventory obsolescence, which could further pressure future gross margins.
According to the latest balance sheet data, ZJYL's debt-to-equity ratio has risen to 0.64 in 2025Q4 from a zero-debt position in 2022, signaling a rapid shift toward debt-financed operations that may limit the company's ability to navigate future economic downturns or industry-specific shocks.
The emergence of debt, coupled with a lack of consistent interest coverage, suggests that the company's financial position is becoming increasingly vulnerable. Investors should monitor whether this leverage is being used to fund necessary operational improvements or simply to bridge persistent cash flow deficits.
The P/E ratio is frequently misapplied to ZJYL, as it obscures the company's reliance on non-operating income and government subsidies to bolster net margins, which may not reflect the true, sustainable earning power of its core manufacturing business model.
Analysts should instead focus on operating cash flow and EBITDA, as these metrics provide a clearer view of the company's ability to generate cash from its primary operations. Relying on P/E in this context may lead to an overly optimistic assessment of the firm's profitability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZJYL stock.
Jin Medical International Ltd.'s current P/E ratio is 12.7x. The historical average is 83.0x.
Jin Medical International Ltd.'s current EV/EBITDA is 28.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 54.0x.
Jin Medical International Ltd.'s return on equity (ROE) is 4.1%. The historical average is 21.4%.
Based on historical data, Jin Medical International Ltd. is trading at a P/E of 12.7x. Compare with industry peers and growth rates for a complete picture.
Jin Medical International Ltd. has 29.2% gross margin and 2.9% operating margin.
Jin Medical International Ltd.'s Debt/EBITDA ratio is 20.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.